Ocular surface changes following oral anticholinergic use for overactive bladder.
OBJECTIVE
To investigate the effect of oral solifenacin succinate on Schirmer I test results, tear break-up time (TBUT) and Ocular Surface Disease Index (OSDI) scores in overactive bladder (OAB) patients and to compare these results with those of healthy control subjects.


METHODS
The female OAB patients who were prescribed oral solifenacin succinate 5 mg/day (Group I, N = 80) and age-matched healthy female subjects (Group II, N = 40) were recruited for the study and underwent ophthalmological examination prior to oral treatment and after 4 weeks. They completed the OSDI questionnaire and underwent ocular surface tests including Schirmer I test and TBUT.


RESULTS
The statistical analysis of the Schirmer I test and TBUT revealed no significant difference between the baseline and 4th week values in both groups (Group I, p = 0.506 and p = 0.070 consecutively) (Group II, p = 0.810 and p = 0.823 consecutively). OSDI scores were found to be significantly increased in group I (21.8 ± 4.2 vs 23.1 ± 4.6, p = 0.020) and remained unchanged in group II (20.5 ± 7.0 vs 20.7 ± 7.0, p = 0.805).


CONCLUSIONS
Short-term solifenacin succinate treatment has no effect on the Schirmer I test results and TBUT, but ocular surface symptoms appeared to be exacerbated in respect with increased OSDI scores. However, the clinical significance needs to be further evaluated with larger studies.
a Ophthalmology Department, Ulucanlar Eye Training and Research Hospital , Ankara , Turkey .
Mehmet Ali
MA
Sekeroglu
b Ophthalmology Department and.
Emre
E
Hekimoglu
c Urogynecology Department, Etlik Zubeyde Hanim Maternity and Research Hospital , Ankara , Turkey , and.
Yasemin
Y
Tasci
c Urogynecology Department, Etlik Zubeyde Hanim Maternity and Research Hospital , Ankara , Turkey , and.
Ismail
I
Dolen
d Biostatistics Department, Hacettepe University Faculty of Medicine , Ankara , Turkey.
Umut
U
Arslan
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018680:Cholinergic Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D005123:Eye / Q000187:drug effects*; D005260:Female; D006801:Humans; D008875:Middle Aged; D000069464:Solifenacin Succinate / Q000009:adverse effects* / Q000627:therapeutic use; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*
D018680:Cholinergic Antagonists; D000069464:Solifenacin Succinate
Dry eye; Schirmer test; ocular surface; tear break-up time